| Drug General Information |
| Drug ID |
D09LAQ
|
| Former ID |
DNC003186
|
| Drug Name |
Cyclic Guanosine Monophosphate
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C10H12N5O7P
|
| InChI |
InChI=1S/C10H12N5O7P/c11-10-13-7-4(8(17)14-10)12-2-15(7)9-5(16)6-3(21-9)1-20-23(18,19)22-6/h2-3,5-6,9,16H,1H2,(H,18,19)(H3,11,13,14,17)/t3-,5-,6-,9-/m1/s1
|
| InChIKey |
ZOOGRGPOEVQQDX-UUOKFMHZSA-N
|
| CAS Number |
CAS 7665-99-8
|
| PubChem Compound ID |
|
| PubChem Substance ID |
4194, 825087, 826483, 830045, 831843, 841464, 7885238, 7889740, 14900537, 16415368, 24778932, 26703232, 29291398, 49693485, 49746466, 49854172, 50096566, 50315835, 53777030, 53777035, 53777038, 53790146, 56311215, 57331663, 92298285, 103526857, 104359789, 121270428, 126523956, 129932460, 134988190, 135651454, 137231635, 137249688, 152256021, 160848229, 162221115, 163724378, 165248680, 172096870, 172097238, 175443186, 177012389, 184611498, 186009741, 188377283, 189158863, 198946721, 219402225, 223557137
|
| Target and Pathway |
| Target(s) |
CGMP-dependent3',5'-cyclic phosphodiesterase |
Target Info |
Inhibitor |
[2]
|
|---|
| CAMP-dependent protein kinase type I-alpha regulatory chain |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
Purine metabolism
|
|
cGMP-PKG signaling pathway
|
|
Morphine addictionhsa04210:Apoptosis
|
|
Insulin signaling pathway
|
|
NetPath Pathway
|
TSH Signaling PathwayNetPath_25:FSH Signaling Pathway
|
|
PANTHER Pathway
|
Endothelin signaling pathway
|
|
Hedgehog signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Metabotropic glutamate receptor group III pathway
|
|
Metabotropic glutamate receptor group II pathway
|
|
Metabotropic glutamate receptor group I pathway
|
|
Muscarinic acetylcholine receptor 2 and 4 signaling pathway
|
|
Transcription regulation by bZIP transcription factor
|
|
GABA-B receptor II signaling
|
|
Pathway Interaction Database
|
Alpha4 beta1 integrin signaling events
|
|
PathWhiz Pathway
|
Muscle/Heart Contraction
|
|
Reactome
|
cGMP effects
|
|
G alpha (s) signalling eventsR-HSA-163615:PKA activation
|
|
PKA activation in glucagon signalling
|
|
DARPP-32 events
|
|
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
|
|
Vasopressin regulates renal water homeostasis via Aquaporins
|
|
Hedgehog 'off' state
|
|
Factors involved in megakaryocyte development and platelet production
|
|
WikiPathways
|
SIDS Susceptibility Pathways
|
|
Calcium Regulation in the Cardiac Cell
|
|
G Protein Signaling Pathways
|
|
Myometrial Relaxation and Contraction Pathways
|
|
Mesodermal Commitment Pathway
|
|
DAG and IP3 signaling
|
|
Regulation of Water Balance by Renal Aquaporins
|
|
miRs in Muscle Cell Differentiation
|
|
Opioid Signalling
|
|
Integration of energy metabolism
|
|
Factors involved in megakaryocyte development and platelet production
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2347). |
|---|
| REF 2 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. |
|---|
